Table 4.
Results of Cox regression analysis for time to PSA progression.
| Variables (Reference) | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age ≥ 65 years (<65 years) | 1.95 (0.80–4.75) | 0.143 | 1.41 (0.53–3.74) | 0.494 |
| Obesity (non-obesity) | 0.34 (0.13–0.87) | 0.025 | 2.53 (0.47–13.47) | 0.278 |
| Sarcopenia (no sarcopenia) | 16.07 (2.16–119.46) | 0.007 | 12.91 (1.08–153.85) | 0.043 |
| SFI ≥ median (<median) | 0.31 (0.13–0.75) | 0.009 | 0.29 (0.06–1.34) | 0.114 |
| VFI ≥ median (<median) | 1.15 (0.51–2.58) | 0.734 | ||
| VSR ≥ median (<median) | 1.75 (0.76–4.01) | 0.185 | ||
| PSA ≥ median (<median) | 1.84 (0.78–4.30) | 0.162 | 1.12 (0.40–3.10) | 0.832 |
| Abiraterone acetate (docetaxel) | 1.18 (0.48–2.87) | 0.720 | ||
| ECOG PS ≥ 1 (0) | 3.65 (1.44–9.22) | 0.006 | 2.73 (1.04–7.14) | 0.041 |
| Gleason score ≥ 8 (<8) | N/A | 0.958 | ||
| Stage cT4 (≤cT3) | 0.59 (0.24–1.43) | 0.246 | ||
| Regional LN metastasis (no) | 2.03 (0.61–6.82) | 0.250 | ||
| Bone metastasis (no) | 6.01 (0.81–44.67) | 0.079 | 0.43 (0.04–5.04) | 0.500 |
| Visceral metastasis (no) | 1.39 (0.60–3.26) | 0.446 | ||
| High-volume (low-volume) | 8.62 (1.16–64.07) | 0.035 | 1.37 (0.16–11.96) | 0.773 |
| High-risk (low-risk) | N/A | 0.950 | N/A | 0.954 |
Variables with p < 0.10 in the univariable analysis are entered into the multivariable analysis, with age, baseline PSA level, disease volume, and disease risk being fixed.